Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
Development of Blood Vessels01:07

Development of Blood Vessels

2.0K
The development of the vascular system in a fetus is a complex and intricate process that begins as early as 15 to 16 days post-conception. This process starts outside the embryo, specifically in the mesoderm of the yolk sac, chorion, and connecting stalk. Approximately two days later, the formation of blood vessels occurs within the embryo itself.
The initial formation of this system is facilitated by the small amount of yolk present in the ovum and yolk sac. Blood vessels originate from...
2.0K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.4K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Rapid 3D Melanoma-Skin Organoid for High-Throughput Assessment of Tumor Dynamics and Drug Response.

International journal of molecular sciences·2026
Same author

Enhancing Patient Lymphocyte Response to Peritoneal Malignancies Using a Personalized Immunocompetent Microfluidic Co-Culture Platform.

bioRxiv : the preprint server for biology·2026
Same author

Immune-reactive tumor organoids system to determine the effects of microbial metabolites on cancer immunity and immunotherapies.

Frontiers in microbiomes·2026
Same author

A Multiaxial Bioreactor Integrated with an Environmental Monitoring System for Tissue-Engineered Skin Grafts.

Advanced healthcare materials·2026
Same author

The effect of stiffness on cell behavior and drug resistance in patient-derived breast cancer organoids.

Acta biomaterialia·2025
Same author

A Bioengineered Skin Organoid Platform for Modeling Human Skin Physiology and Cytotoxicity.

Research square·2025
Same journal

TNF inhibitors for the long-term management of juvenile idiopathic arthritis associated uveitis: real-life data from the ITHACA cohort.

Expert opinion on biological therapy·2026
Same journal

Type 2 inflammation and biologics: a twenty-year journey.

Expert opinion on biological therapy·2026
Same journal

Current outlook on the use of biological agents to improve outcomes in adult secondary hemophagocytic lymphohistiocytosis.

Expert opinion on biological therapy·2026
Same journal

Addressing challenges in disease management of childhood-onset systemic lupus erythematosus: the role of biologics, with primary focus on rituximab and belimumab.

Expert opinion on biological therapy·2026
Same journal

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026
Same journal

Optimizing biologic therapy in psoriasis: dose adjustment, treatment duration, and tapering-an expert perspective.

Expert opinion on biological therapy·2026
See all related articles

Related Experiment Video

Updated: May 3, 2026

Engineering Biological-Based Vascular Grafts Using a Pulsatile Bioreactor
11:22

Engineering Biological-Based Vascular Grafts Using a Pulsatile Bioreactor

Published on: June 14, 2011

16.8K

Bioengineered blood vessels.

Guoguang Niu1, Etai Sapoznik, Shay Soker

  • 1Wake Forest Institute for Regenerative Medicine, Wake Forest Baptist Medical Center, Medical Center Boulevard , Winston-Salem, NC 27157 , USA +1 336 713 7295 ; +1 336 713 7290 ; ssoker@wfubmc.edu.

Expert Opinion on Biological Therapy
|January 28, 2014
PubMed
Summary
This summary is machine-generated.

Tissue-engineered blood vessels (TEBVs) offer alternatives for cardiovascular disease (CVD) patients needing vascular grafts. Current TEBV designs require further development for widespread clinical use.

More Related Videos

Scaling of Engineered Vascular Grafts Using 3D Printed Guides and the Ring Stacking Method
09:38

Scaling of Engineered Vascular Grafts Using 3D Printed Guides and the Ring Stacking Method

Published on: March 27, 2017

8.1K
Microfluidic Bioprinting for Engineering Vascularized Tissues and Organoids
08:22

Microfluidic Bioprinting for Engineering Vascularized Tissues and Organoids

Published on: August 11, 2017

15.5K

Related Experiment Videos

Last Updated: May 3, 2026

Engineering Biological-Based Vascular Grafts Using a Pulsatile Bioreactor
11:22

Engineering Biological-Based Vascular Grafts Using a Pulsatile Bioreactor

Published on: June 14, 2011

16.8K
Scaling of Engineered Vascular Grafts Using 3D Printed Guides and the Ring Stacking Method
09:38

Scaling of Engineered Vascular Grafts Using 3D Printed Guides and the Ring Stacking Method

Published on: March 27, 2017

8.1K
Microfluidic Bioprinting for Engineering Vascularized Tissues and Organoids
08:22

Microfluidic Bioprinting for Engineering Vascularized Tissues and Organoids

Published on: August 11, 2017

15.5K

Area of Science:

  • Biomedical Engineering
  • Regenerative Medicine
  • Cardiovascular Research

Background:

  • Cardiovascular disease (CVD) remains a global health challenge, with vascular grafting a common treatment for diseased vessels.
  • Autologous vascular grafts are often unavailable in CVD patients, necessitating alternative solutions.
  • Tissue-engineered blood vessels (TEBVs) emerge as a promising alternative to autologous grafts.

Discussion:

  • This review explores scaffolding systems, cell sources, and conditioning methods for TEBV fabrication.
  • Assessment methods for TEBV functionality and results from preclinical and clinical trials are presented.
  • Current TEBV designs face limitations hindering their clinical viability.

Key Insights:

  • TEBVs utilize advanced tissue engineering to create functional blood vessels.
  • Diverse approaches in scaffolding, cell sourcing, and conditioning are being investigated.
  • Despite progress, TEBV functionality and integration require significant improvement for clinical success.

Outlook:

  • Further research into vascular development principles can enhance TEBV design and function.
  • Optimizing TEBV fabrication and preclinical testing is crucial for clinical translation.
  • Advancements in TEBV technology hold potential to revolutionize vascular reconstruction for CVD patients.